Otulfi (Ustekinumab)

Ustekinumab, the active ingredient in Otulfi, is a biologic presented as a injection for subcutaneous use. It modulates immune responses and is indicated for several chronic inflammatory conditions in adults. GNH USA supplies Otulfi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide.

Ustekinumab is a monoclonal antibody that targets key cytokines involved in the inflammatory cascade of immune‑mediated diseases. - Plaque psoriasis: reduces skin lesions and improves quality of life. - Crohn’s disease: induces and maintains clinical remission. - Ulcerative colitis: helps achieve mucosal healing and symptom control. - Psoriatic arthritis: alleviates joint pain and prevents structural damage.

Adverse reactions to ustekinumab vary in frequency and severity.

Common Side Effects: - Injection site pain - Upper respiratory tract infection - Headache - Fatigue - Nausea - Diarrhea

Serious or Rare Side Effects: - Severe infections (e.g., tuberculosis) - Malignancies such as lymphoma - Hypersensitivity reactions - Cardiovascular events - New onset or worsening inflammatory bowel disease - Neurologic disorders including demyelination

Ustekinumab should be used under careful medical supervision, with attention to infection risk and immune status. - Screen for latent TB: perform interferon‑gamma release assay before initiation. - Monitor for signs of infection: advise patients to report fever, cough, or unexplained malaise. - Assess vaccination status: avoid live vaccines during treatment.\n- Review cardiac history: use cautiously in patients with known cardiovascular disease. - Pregnancy and lactation: weigh benefits against potential risks; discuss with a specialist. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Ustekinumab may interact with other agents that affect immune function or infection risk.

Major Interactions (Avoid): - Live vaccines: concurrent use can cause severe infection. - Systemic immunosuppressants (e.g., high‑dose corticosteroids): may increase infection risk.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., azoles): may require infection monitoring. - Antiviral therapies: observe for altered immune response. - Cytokine‑targeting biologics: assess cumulative immunosuppression. - Concomitant antibiotics: monitor for opportunistic infections.